π¬ Prostate cancer watch vs. focal therapy trends
Active surveillance rates are significantly increasing among US veterans with low-risk prostate cancer, according to VA data. Meanwhile, over 15,000 patients received focal therapy between 2010 and 2023 nationally. This trend is notable because focal therapy currently lacks strong, high-quality supporting evidence. The studies, published on August 13 in JAMA, highlight progress in surveillance but raise concerns about focal therapy use. Future focus will be on solidifying evidence for these treatment modalities. π§